Toward Precision Medicine With Next-Generation EGFR Inhibitors in Non-Small-Cell Lung Cancer

Pharmacogenomics and Personalized Medicine - New Zealand
doi 10.2147/pgpm.s55339
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Oncology in Clinical Practice
Oncology
2019English

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2015English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy
OncologyPharmacology
2016English

Reverse of EGFR Inhibitors Resistance by Co-Delivering EGFR and Integrin Αvβ3 Inhibitors With Nanoparticles in Non-Small Cell Lung Cancer

Bioscience Reports
BiochemistryCell BiologyMolecular BiologyBiophysics
2019English

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Expert Review of Anticancer Therapy
OncologyPharmacology
2019English

Using Stem Cell Biology to Design Precision Medicine for Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma

PLoS ONE
Multidisciplinary
2013English

P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastases

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

EGFR Mutations Status for Non-Small-Cell Lung Cancer Patients

Sveikatos mokslai
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy